Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of...
December 14, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
November 10, 2021 16:15 ET | Source: Vera Therapeutics

Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
November 10, 2021 07:15 ET | Source: Vera Therapeutics

Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a...
November 04, 2021 16:05 ET | Source: Vera Therapeutics

Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021

Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent...
October 13, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
September 09, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics Hosting Key Opinion Leader Webinar on IgA Nephropathy

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
August 16, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological...
July 14, 2021 07:30 ET | Source: Vera Therapeutics

Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...
June 24, 2021 07:15 ET | Source: Vera Therapeutics

Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4 million in May 2021 - - -Expanded the management team to...